A non-synonymous polymorphism in NBS1 is associated with progression from chronic hepatitis B virus infection to hepatocellular carcinoma in a Chinese population

Low Frequency of Cancer-Predisposition Gene Mutations in Liver Transplant Candidates with Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) mainly stems from liver cirrhosis and its genetic predisposition is believed to be rare. However, two recent studies describe pathogenic/likely pathogenic germline variants (PV) in cancer-predisposition genes (CPG). As the risk of de novo tumors might be increased in PV carriers, especially in immunosuppressed patients after a liver transplantation, we analyzed the prevalence of germline CPG variants in HCC patients considered for liver transplantation. Using the panel NGS targeting 226 CPGs, we analyzed germline DNA from 334 Czech HCC patients and 1662 population-matched controls. We identified 48 PVs in 35 genes in 47/334 patients (14.1%). However, only 7/334 (2.1%) patients carried a PV in an established CPG (PMS2, 4×NBN, FH or RET). Only the PV carriers in two MRN complex genes (NBN and RAD50) were significantly more frequent among patients over controls. We found no differences in clinicopathological characteristics between carriers and non-carriers. Our study indicated that the genetic component of HCC is rare. The HCC diagnosis itself does not meet criteria for routine germline CPG genetic testing. However, a low proportion of PV carriers may benefit from a tailored follow-up or targeted therapy and germline testing could be considered in liver transplant recipients.

Development of a novel analytical method for inflammation and immunity-related metabolites in serum based on liquid chromatography tandem mass spectrometry

Some metabolites have been found to play key roles in inflammation and immunity events that are associated with diseases such as cancer, diabetes and cytokine release syndrome. Characterization upon the inflammation and immunity-related metabolites (IIMs) will be helpful to the assessment of related pathological states. Although these metabolites have been partially reported in previous studies, the methods for specific measurement of them remain lacking. In the present study, a liquid chromatography - mass spectrometry based method was developed for the targeted analyses of 45 IIMs including amino acids, organic acids, phosphatidylcholines (PCs), polyunsaturated fatty acids and hormones selected based on the literature knowledge. Direct extraction with dansyl-chloride in acetonitrile was proved to be the most efficient and time-saving strategy, in which precipitation, extraction and derivatization were integrated. IIMs derivatized for 4 min and quenched for 2 min revealed the most comprehensive abundance. Based on the defined conditions, all the IIMs had a low limit of detection smaller than 1 ng/mL with the linear range greater than three orders of magnitude. The relative standard derivations of intra-day and inter-day precisions were ranged from 2.2% to 13.4% and 1.7% to 19.5%, respectively. The recovery rates and accuracy in low concentration were 98.9% ± 5.6% and 106.7% ± 11.6%, in medium concentration were 97.1% ± 6.8% and 106.9% ± 9.5%, and in high concentration were 98.4% ± 8.9% and 98.1% ± 8.1%, respectively. Matrix effect and stability were ranged from -37.8% to 35.6% and 2.9% to 14.2%, respectively. To show the usefulness of the method, serum IIMs in hepatitis B virus (HBV) infected patients and healthy subjects were determined and compared. Bile acids, lipoxygenase-mediated lipid mediators and non-enzymatic products showed global increases, whereas most of LysoPCs and cyclooxygenase-mediated prostaglandin D2 decreased in HBV serum samples. This study provided a robust approach for the characterization of IIMs.

Genetic polymorphisms in DNA repair genes and hepatocellular carcinoma risk

Hepatocellular carcinoma (HCC) is one of the most frequent types of tumors worldwide. Its occurrence and development have been related to various risk factors, such as chronic infection with hepatitis B or C viruses and alcohol addiction. DNA repair systems play a critical role in maintaining the integrity of the genome. Defects in these systems have been related to increased susceptibility to various types of cancer. Multiple genetic polymorphisms in genes of DNA repair systems have been reported that may affect DNA repair capacity (DRC) and modulate risk to cancer. Several studies have been conducted to assess the role of polymorphisms of DNA repair genes on the HCC risk. Identifying these polymorphisms and their association with HCC risk may help to improve prevention and treatment strategies. In this study, we review investigations that evaluated the association between genetic polymorphisms of DNA repair genes and risk of HCC.

The role of DNA damage and repair in liver cancer

Hepatocellular carcinoma is rapidly becoming a major cause of global mortality due to the ever-increasing prevalence of obesity. DNA damage is known to play an important role in cancer initiation, however DNA repair systems are also vital for the survival of cancer cells. Given the function of the liver and its exposure to the gut, it is likely that DNA damage and repair would be of particular importance in hepatocellular carcinoma. However, many contemporary reports have neglected the role of individual pathways of DNA damage and repair in their hypotheses. This review, therefore, aims to provide a concise overview for researchers in the field of liver cancer to understand the pathways of DNA damage and repair and their individual roles in hepatocellular carcinoma.

Upregulation of Holliday junction recognition protein predicts poor prognosis and biochemical recurrence in patients with prostate cancer

Abnormal expression of Holliday junction recognition protein (HJURP) in several types of tumor cells plays a vital role in the formation and progression of tumors. Few studies have investigated the role of HJURP in prostate cancer (PCa). The aim of this study was to analyze the expression levels of HJURP in PCa and to establish the association with clinicopathological data. Reverse transcription quantitative polymerase chain reaction and immunohistochemical analysis were used to detect the expression levels of HJURP in benign and PCa prostate tissues. The Taylor dataset was statistically analyzed to determine if HJURP expression levels were associated with PCa clinicopathological data. HJURP was overexpressed in PCa tissues compared with benign prostate tissues. Statistical analysis of the Taylor dataset indicated that upregulation of HJURP was significantly associated with positive prostate-specific antigen (PSA) levels (P=0.004), high Gleason score (P=0.005), advanced pathological stage (P=0.007), metastasis (P<0.001) and PSA failure (P<0.001). Higher HJURP mRNA expression levels were significantly associated with shorter biochemical recurrence (BCR)-free survival (P<0.001). To the best of our knowledge, this study is the first report of HJURP upregulation in PCa tissues. Upregulation of HJURP may predict BCR-free survival and HJURP may be an oncogene that impacts the prognosis of patients with PCa.